Literature DB >> 2606186

Fatal asthma in a young patient with severe bronchial hyperresponsiveness but stable peak flow records.

M Saetta1, G Thiene, S Crescioli, L M Fabbri.   

Abstract

We report the sudden death of a 16 yr old boy with asthma. At presentation, the patient had symptoms of active asthma, mild bronchoconstriction, severe airway hyperresponsiveness to methacholine, and increased variability of peak expiratory flow records. After the patient was placed on inhaled beclomethasone (1 mg b.i.d preceded by inhaled fenoterol 0.4 mg b.i.d) he rapidly felt better, lung function improved, but airway responsiveness remained severe. Four months later, on the day he died, he was well until a fatal attack of asthma occurred around midnight without identifiable precipitating factors. Taken to hospital, he was dead on arrival. Necroscopy and microscopy showed the characteristic features of asthma death. This case report suggests that; a) asthma death may occur suddenly and unexpectedly; b) asthma death may not be prevented by long-term treatment with high-dose inhaled beclomethasone; c) severe bronchial hyperresponsiveness, even in the presence of stable peak flow records, may identify asthmatic patients at risk of sudden death.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606186

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

1.  Bronchial hyperresponsiveness following acute severe asthma.

Authors:  A Rabbat; J P Laaban; E Orvoën-Frija; M F Doré; A Achkar; J Rochemaure
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

2.  Single breath counting for the evaluation of pediatric respiratory function: derivation of a "normogram".

Authors:  Lawrence Edward Kass; Kristy Putnam
Journal:  Intern Emerg Med       Date:  2015-09-28       Impact factor: 3.397

3.  Rapid onset asthma: a severe but uncommon manifestation.

Authors:  J Kolbe; W Fergusson; J Garrett
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.